Page last updated: 2024-11-03

procarbazine and Tumor Lysis Syndrome

procarbazine has been researched along with Tumor Lysis Syndrome in 1 studies

Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.

Tumor Lysis Syndrome: A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mahajan, A1
Nirmal, S1
English, MW1
Jenney, ME1
Lazda, ED1

Other Studies

1 other study available for procarbazine and Tumor Lysis Syndrome

ArticleYear
Acute tumor lysis syndrome in Hodgkin disease.
    Medical and pediatric oncology, 2002, Volume: 39, Issue:1

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Chlorambucil; Hodgk

2002